Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Antibodies Market: Global Industry Analysis and Opportunity Assessment 2016 – 2026

Table of Content

1. Executive Summary

2. Assumptions and Acronyms

3. Research Methodology

4. Antibodies Market Overview

4.1. Introduction

4.1.1. Antibodies Market Definition

4.1.2. Antibodies Market Taxonomy

4.1.3. Antibodies Market Product Type Overview

4.1.4. Overview

4.2. Antibodies Market Dynamics

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Opportunity

4.3. Regulations

5. Global Antibodies Market Forecast

5.1. Market Value (US$ Mn) Forecast

5.1.1. Y-o-Y Growth Projections

5.1.2. Absolute $ Opportunity

5.2. Antibodies Market Trends

5.2.1. Market Share, By Region

5.2.2. Market Share, By Product Type

5.2.3. Market Share, By End User

5.2.4. Market Share, By Disease Indication

6. Global Antibodies Market Analysis, By Product Type

6.1. Introduction

6.1.1. Y-o-Y Growth Comparison, By Product Type

6.1.2. Market Share & Basis Point (BPS) Analysis, By Product Type

6.2. Market Forecast, By Product Type

6.2.1. Monoclonal antibodies

6.2.1.1. Absolute $ Opportunity

6.2.1.2. Market Value (US$ Mn) Forecast

6.2.2. Polyclonal antibodies

6.2.2.1. Absolute $ Opportunity

6.2.2.2. Market Value (US$ Mn) Forecast

6.2.3. Antibody-drug complexes (ADCs)

6.2.3.1. Absolute $ Opportunity

6.2.3.2. Market Value (US$ Mn) Forecast

6.3. Market Attractiveness Analysis, By Product Type

6.4. Prominent Trends

7. Global Antibodies Market Analysis, By Disease Indication

7.1. Introduction

7.1.1. Y-o-Y Growth Comparison, By Disease Indication

7.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication

7.2. Market Forecast, By Disease Indication

7.2.1. Cardiovascular diseases

7.2.1.1. Absolute $ Opportunity

7.2.1.2. Market Value (US$ Mn) Forecast

7.2.2. CNS disorders

7.2.2.1. Absolute $ Opportunity

7.2.2.2. Market Value (US$ Mn) Forecast

7.2.3. Cancer

7.2.3.1. Absolute $ Opportunity

7.2.3.2. Market Value (US$ Mn) Forecast

7.2.4. Autoimmune Disorders

7.2.4.1. Absolute $ Opportunity

7.2.4.2. Market Value (US$ Mn) Forecast

7.3. Market Attractiveness Analysis, By Disease Indication

7.4. Prominent Trends

8. Global Antibodies Market Analysis, By End User

8.1. Introduction

8.1.1. Y-o-Y Growth Comparison, By End User

8.1.2. Market Share & Basis Point (BPS) Analysis, By End User

8.2. Market Forecast, By End User

8.2.1. Hospitals

8.2.1.1. Absolute $ Opportunity

8.2.1.2. Market Value (US$ Mn) Forecast

8.2.2. Long-term Care Facilities

8.2.2.1. Absolute $ Opportunity

8.2.2.2. Market Value (US$ Mn) Forecast

8.2.3. Research institutes

8.2.3.1. Absolute $ Opportunity

8.2.3.2. Market Value (US$ Mn) Forecast

8.3. Market Attractiveness Analysis, By End User

8.4. Prominent Trends

9. Global Antibodies Market Analysis, By Region

9.1. Introduction

9.1.1. Y-o-Y Growth Projections, By Region

9.1.2. Market Share & Basis Point (BPS) Analysis, By Region

9.2. Market Forecast, By Region

9.2.1. North America Market Value (US$ Mn) Forecast

9.2.2. Latin America Market Value (US$ Mn) Forecast

9.2.3. Western Europe Market Value (US$ Mn) Forecast

9.2.4. Eastern Europe Market Value (US$ Mn) Forecast

9.2.5. Asia Pacific Excl. Japan Market Value (US$ Mn) Forecast

9.2.6. Japan Market Value (US$ Mn) Forecast

9.2.7. MEA Market Value (US$ Mn) Forecast

9.3. Regional Attractiveness Analysis

10. North America Antibodies Market Analysis

10.1. Introduction

10.1.1. Y-o-Y Growth Projections, By Country

10.1.2. Market Share & Basis Point (BPS) Analysis, By Country

10.2. Key Regulations

10.3. Key Trends

10.4. North America Market Forecast

10.4.1. Market Value (US$ Mn) Forecast, By Country

10.4.1.1. U.S. Absolute $ Opportunity

10.4.1.2. Canada Absolute $ Opportunity

10.4.2. Market Value (US$ Mn) Forecast, By Product Type

10.4.2.1. Monoclonal antibodies

10.4.2.2. Polyclonal antibodies

10.4.2.3. Antibody-drug complexes (ADCs)

10.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

10.4.3.1. Cardiovascular diseases

10.4.3.2. CNS disorders

10.4.3.3. Cancer

10.4.3.4. Autoimmune Disorders

10.4.4. Market Value (US$ Mn) Forecast, By End User

10.4.4.1. Hospitals

10.4.4.2. Long-term Care Facilities

10.4.4.3. Research institutes

10.5. Market Attractiveness Analysis

10.5.1. By Country

10.5.2. By Product Type

10.5.3. By End User

10.5.4. By Disease Indication

10.6. Drivers & Restraints: Impact Analysis

11. Latin America Antibodies Market Analysis

11.1. Introduction

11.1.1. Y-o-Y Growth Projections, By Country

11.1.2. Market Share & Basis Point (BPS) Analysis, By Country

11.2. Key Regulations

11.3. Key Trends

11.4. Latin America Market Forecast

11.4.1. Market Value (US$ Mn) Forecast, By Country

11.4.1.1. Argentina Absolute $ Opportunity

11.4.1.2. Brazil Absolute $ Opportunity

11.4.1.3. Mexico Absolute $ Opportunity

11.4.1.4. Rest of Latin America Absolute $ Opportunity

11.4.2. Market Value (US$ Mn) Forecast, By Product Type

11.4.2.1. Monoclonal antibodies

11.4.2.2. Polyclonal antibodies

11.4.2.3. Antibody-drug complexes (ADCs)

11.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

11.4.3.1. Cardiovascular diseases

11.4.3.2. CNS disorders

11.4.3.3. Cancer

11.4.3.4. Autoimmune Disorders

11.4.4. Market Value (US$ Mn) Forecast, By End User

11.4.4.1. Hospitals

11.4.4.2. Long-term Care Facilities

11.4.4.3. Research institutes

11.5. Market Attractiveness Analysis

11.5.1. By Country

11.5.2. By Product Type

11.5.3. By End User

11.5.4. By Disease Indication

11.6. Drivers & Restraints: Impact Analysis

12. Western Europe Antibodies Market Analysis

12.1. Introduction

12.1.1. Y-o-Y Growth Projections, By Country

12.1.2. Market Share & Basis Point (BPS) Analysis, By Country

12.2. Key Regulations

12.3. Key Trends

12.4. Western Europe Market Forecast

12.4.1. Market Value (US$ Mn) Forecast, By Country

12.4.1.1. U.K. Absolute $ Opportunity

12.4.1.2. Germany Absolute $ Opportunity

12.4.1.3. France Absolute $ Opportunity

12.4.1.4. Spain Absolute $ Opportunity

12.4.1.5. Italy Absolute $ Opportunity

12.4.1.6. Nordic Countries Absolute $ Opportunity

12.4.1.7. Rest of Western Europe Absolute $ Opportunity

12.4.2. Market Value (US$ Mn) Forecast, By Product Type

12.4.2.1. Monoclonal antibodies

12.4.2.2. Polyclonal antibodies

12.4.2.3. Antibody-drug complexes (ADCs)

12.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

12.4.3.1. Cardiovascular diseases

12.4.3.2. CNS disorders

12.4.3.3. Cancer

12.4.3.4. Autoimmune Disorders

12.4.4. Market Value (US$ Mn) Forecast, By End User

12.4.4.1. Hospitals

12.4.4.2. Long-term Care Facilities

12.4.4.3. Research institutes

12.5. Market Attractiveness Analysis

12.5.1. By Country

12.5.2. By Product Type

12.5.3. By End User

12.5.4. By Disease Indication

12.6. Drivers & Restraints: Impact Analysis

13. Eastern Europe Antibodies Market Analysis

13.1. Introduction

13.1.1. Y-o-Y Growth Projections, By Country

13.1.2. Market Share & Basis Point (BPS) Analysis, By Country

13.2. Key Regulations

13.3. Key Trends

13.4. Eastern Europe Market Forecast

13.4.1. Market Value (US$ Mn) Forecast, By Country

12.4.1.1. Poland Absolute $ Opportunity

12.4.1.2. Russia Absolute $ Opportunity

12.4.1.3. Rest of Eastern Europe Absolute $ Opportunity

13.4.2. Market Value (US$ Mn) Forecast, By Product Type

13.4.2.1. Monoclonal antibodies

13.4.2.2. Polyclonal antibodies

13.4.2.3. Antibody-drug complexes (ADCs)

13.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

13.4.3.1. Cardiovascular diseases

13.4.3.2. CNS disorders

13.4.3.3. Cancer

13.4.3.4. Autoimmune Disorders

13.4.4. Market Value (US$ Mn) Forecast, By End User

13.4.4.1. Hospitals

13.4.4.2. Long-term Care Facilities

13.4.4.3. Research institutes

13.5. Market Attractiveness Analysis

13.5.1. By Country

13.5.2. By Product Type

13.5.3. By End User

13.5.4. By Disease Indication

13.6. Drivers & Restraints: Impact Analysis

14. Asia Pacific Excl. Japan Antibodies Market Analysis

14.1. Introduction

14.1.1. Y-o-Y Growth Projections, By Country

14.1.2. Market Share & Basis Point (BPS) Analysis, By Country

14.2. Key Regulations

14.3. Key Trends

14.4. Asia Pacific Excl. Japan Market Forecast

14.4.1. Market Value (US$ Mn) Forecast, By Country

14.4.1.1. China Absolute $ Opportunity

14.4.1.2. India Absolute $ Opportunity

14.4.1.3. ASEAN Absolute $ Opportunity

14.4.1.4. Australia & New Zealand Absolute $ Opportunity

14.4.1.5. Rest of APEJ Absolute $ Opportunity

14.4.2. Market Value (US$ Mn) Forecast, By Product Type

14.4.2.1. Monoclonal antibodies

14.4.2.2. Polyclonal antibodies

14.4.2.3. Antibody-drug complexes (ADCs)

14.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

14.4.3.1. Cardiovascular diseases

14.4.3.2. CNS disorders

14.4.3.3. Cancer

14.4.3.4. Autoimmune Disorders

14.4.4. Market Value (US$ Mn) Forecast, By End User

14.4.4.1. Hospitals

14.4.4.2. Long-term Care Facilities

14.4.4.3. Research institutes

14.5. Market Attractiveness Analysis

14.5.1. By Country

14.5.2. By Product Type

14.5.3. By End User

14.5.4. By Disease Indication

14.6. Drivers & Restraints: Impact Analysis

15. Japan Antibodies Market Analysis

15.1. Introduction

15.2. Key Regulations

15.3. Key Trends

15.4. Japan Market Forecast

15.4.1. Market Value (US$ Mn) Forecast, By Product Type

15.4.1.1. Monoclonal antibodies

15.4.1.2. Polyclonal antibodies

15.4.1.3. Antibody-drug complexes (ADCs)

15.4.2. Market Value (US$ Mn) Forecast, By Disease Indication

15.4.2.1. Cardiovascular diseases

15.4.2.2. CNS disorders

15.4.2.3. Cancer

15.4.2.4. Autoimmune Disorders

15.4.3. Market Value (US$ Mn) Forecast, By End User

15.4.3.1. Hospitals

15.4.3.2. Long-term Care Facilities

15.4.3.3. Research institutes

15.5. Market Attractiveness Analysis

15.5.1. By Product Type

15.5.2. By End User

15.5.3. By Disease Indication

15.6. Drivers & Restraints: Impact Analysis

16. MEA Antibodies Market Analysis

16.1. Introduction

16.1.1. Y-o-Y Growth Projections, By Country

16.1.2. Market Share & Basis Point (BPS) Analysis, By Country

16.2. Key Regulations

16.3. Key Trends

16.4. MEA Market Forecast

16.4.1. Market Value (US$ Mn) Forecast, By Country

16.4.1.1. GCC Countries Absolute $ Opportunity

16.4.1.2. South Africa Absolute $ Opportunity

16.4.1.3. North Africa Absolute $ Opportunity

16.4.1.4. Rest of MEA Absolute $ Opportunity

16.4.2. Market Value (US$ Mn) Forecast, By Product Type

16.4.2.1. Monoclonal antibodies

16.4.2.2. Polyclonal antibodies

16.4.2.3. Antibody-drug complexes (ADCs)

16.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

16.4.3.1. Cardiovascular diseases

16.4.3.2. CNS disorders

16.4.3.3. Cancer

16.4.3.4. Autoimmune Disorders

16.4.4. Market Value (US$ Mn) Forecast, By End User

16.4.4.1. Hospitals

16.4.4.2. Long-term Care Facilities

16.4.4.3. Research institutes

16.5. Market Attractiveness Analysis

16.5.1. By Country

16.5.2. By Product Type

16.5.3. By End User

16.5.4. By Disease Indication

16.6. Drivers & Restraints: Impact Analysis

17. Competition Landscape

17.1. Company Share Analysis

17.2. Competition Dashboard

17.3. Company Profiles Inclusions

17.3.1. Revenue

17.3.2. Products/Brand Offerings

17.3.3. Key developments

17.3.4. SWOT Analysis

17.4. Company Profiled

17.4.1. Novartis AG

17.4.2. F. Hoffmann-La Roche Ltd.

17.4.3. Johnson & Johnson Services, Inc.

17.4.4. Takeda Pharmaceutical Company Limited

17.4.5. Amgen Inc.

17.4.6. Biogen Inc.

17.4.7. Bristol-Myers Squibb Company

17.4.8. AbbVie Inc.

17.4.9. Sanofi

17.4.10. Eli Lilly and Co.

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote